Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06234267
Other study ID # STUDY00004084
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date April 1, 2025

Study information

Verified date March 2024
Source University of Arizona
Contact Rachel EB Jarrett, MPH
Phone 5206260375
Email rjarrett@email.arizona.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Health behavior text message content will be delivered daily over 4-weeks to cancer survivor/caregiver dyads.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 42
Est. completion date April 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (survivors and caregivers): 1. =18 years old 2. have access to a mobile phone with the ability to receive and send text messages 3. English- or Spanish-speaking 4. free of psychiatric or physical disorders that could interfere with participation (e.g., psychosis, delirium) 5. able to give informed consent in English or Spanish Survivors must also: 1. have been diagnosed with any solid tumor cancer 2. have completed primary curative treatment at least one month prior to enrollment 3. be able to identify a caregiver to enroll in the study with them 4. report difficulty engaging in dietary quality, physical activity, and/or sleep hygiene behaviors at screening. Exclusion Criteria: - Does not meet any of the above criteria

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Eat, Play, Sleep
The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.

Locations

Country Name City State
United States University of Arizona Cancer Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Successful receipt of 95% of text messages sent 4 weeks
Primary Acceptability of text messages measured by self-report 0-4 likert scale of acceptability of each text message, where 5 is greater acceptability 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab